Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

3.820 +0.100 (+2.69%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,829
Open 3.800
Bid (Size) 3.660 (5)
Ask (Size) 4.000 (1)
Prev. Close 3.720
Today's Range 3.650 - 3.900
52wk Range 3.360 - 141.00
Shares Outstanding 988,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual... 
Via Benzinga
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-64.74%
-64.74%
1 Month
-35.25%
-35.25%
3 Month
-69.07%
-69.07%
6 Month
-62.55%
-62.55%
1 Year
-93.89%
-93.89%

More News

Read More
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Agile Therapeutics: Q1 Earnings Insights
Via Benzinga
Agile Therapeutics Earnings Preview
Via Benzinga
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Via Benzinga
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics's Return On Capital Employed Insights
Via Benzinga
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
National Instruments, Nutex Health And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Via Benzinga
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
From Agile Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.